You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
AGI 5198 New
Potent and selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1; IC50 = 70 nM). Selective for mIDH1 over wild-type IDH1 and IDH2. Inhibits production of oncometabolite D-2 hydroxyglutarate. Attenuates growth of glioma cells containing mIDH1, but not wild-type IDH1, in vitro and in vivo. Also inhibits growth of fibrosarcoma and chondrosarcoma cells bearing mIDH1.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 462.56. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||4.32 mL||21.62 mL||43.24 mL|
|2.5 mM||0.86 mL||4.32 mL||8.65 mL|
|5 mM||0.43 mL||2.16 mL||4.32 mL|
|25 mM||0.09 mL||0.43 mL||0.86 mL|
References are publications that support the biological activity of the product.
Rohle et al (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340 626 PMID: 23558169
Li et al (2015) Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-hydroxyglutarate in human chondrosarcoma cells. PLoS ONE 10 e0133813 PMID: 26368816
Badur et al (2018) Oncogenic R132 IDH1 mutations limit NADPH for de novo lipogenesis through (D)2-hydroxyglutarate production in fibrosarcoma cells. Cell Rep. 25 1018 PMID: 30355481
If you know of a relevant reference for AGI 5198, please let us know.
View Related Products by Product Action
Keywords: AGI 5198, AGI 5198 supplier, AGI5198, potent, selective, inhibitor, inhibits, mutant, isocitrate, dehydrogenase, 1, mIDH1, oncometabolites, D-2, hydroxyglutarate, D-2HG, Isocitrate, (IDH1), 7087, Tocris Bioscience
Citations for AGI 5198
Citations are publications that use Tocris products.
Currently there are no citations for AGI 5198. Do you know of a great paper that uses AGI 5198 from Tocris? Please let us know.
Reviews for AGI 5198
There are currently no reviews for this product. Be the first to review AGI 5198 and earn rewards!
Have you used AGI 5198?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.